Report finds nirsevimab 80% effective at preventing RSV-associated ICU admissions
Nirsevimab was found to be 80% effective at preventing respiratory syncytial virus-associated intensive care unit admissions during the 2024-2025 RSV season, according to a Centers for Disease Control and Prevention report released Nov. 20. It also found the treatment to be 83% effective at preventing acute respiratory failure among infants admitted to an ICU with symptoms during their first RSV season. “These estimates support the recommendation for use of nirsevimab as a prevention strategy to protect infants against severe outcomes from RSV infection,” the CDC said.
Related News Articles
Blog
Even before the COVID pandemic, the mental health and wellness of our young people was failing. The pandemic exacerbated the crisis and made it difficult for…
Headline
A new AHA video highlights how Corewell Health is transforming youth behavioral health care access in rural Michigan through school-based clinics and…
Headline
The AHA has updated the Stress and Coping Resources website, which contains valuable information and resources to support mental well-being for both health…
Headline
Jason Lesandrini, Ph.D., assistant vice president of ethics, advanced care planning, spiritual health and language access services at Wellstar Health System,…
Blog
When I delivered my first baby in 2016, I did not understand how I would feel postpartum. Though I had many family members who had experienced birth and…
Headline
The AHA's Advancing Health podcast recently celebrated the end of 2024 by releasing highlights from some of its most popular episodes of the year. The roundup…